VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · IEX Real-Time Price · USD
2.130
-0.020 (-0.93%)
At close: Jul 19, 2024, 4:30 PM
2.070
-0.060 (-2.82%)
Pre-market: Jul 22, 2024, 9:12 AM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2023. The number of employees decreased by 2 or -16.67% compared to the previous year.
Employees
10
Change (1Y)
-2
Growth (1Y)
-16.67%
Revenue / Employee
$42,300
Profits / Employee
-$2,907,900
Market Cap
30.95M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
Cutera | 430 |
IRIDEX | 111 |
NKGen Biotech | 63 |
Equillium | 44 |
Quince Therapeutics | 32 |
MiNK Therapeutics | 31 |
Longeveron | 24 |
VYNE News
- 26 days ago - VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum - GlobeNewsWire
- 5 weeks ago - VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202 - GlobeNewsWire
- 2 months ago - VYNE Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 4 months ago - VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 5 months ago - VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium - GlobeNewsWire